BTS 74,398

From Wikipedia, the free encyclopedia
BTS 74,398
Systematic (IUPAC) name
1-([1-(3,4-dichlorophenyl)cyclobutyl]-2-(3-diaminethylaminopropylthio)ethanone
Clinical data
Legal status ?
Identifiers
ATC code ?
PubChem CID 24838024
ChemSpider 26325181 YesY
Chemical data
Formula C19H29Cl2N3OS 
Mol. mass 418.423 g/mol
 YesY (what is this?)  (verify)

BTS 74,398 is a centrally acting stimulant drug which was developed for the treatment of Parkinson's disease. It inhibits the synaptic reuptake of dopamine, serotonin and noradrenaline, making it a triple reuptake inhibitor.[1] It was effective in animal models of Parkinson's disease,[2][3] but was unsuccessful in human trials.[4]

References

  1. Lane EL, Cheetham S, Jenner P. Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. Journal of Pharmacology and Experimental Therapeutics. 2005 Mar;312(3):1124-31. PMID 15542624
  2. Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates. Movement Disorders. 2004 Jan;19(1):15-21. PMID 14743355
  3. Lane EL, Cheetham SC, Jenner P. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours. European Journal of Neuroscience. 2005 Jan;21(1):179-86. PMID 15654855
  4. Lane EL, Cheetham S, Jenner P. Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398. Journal of Neural Transmission. 2008;115(3):423-9. PMID 18250952


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.